🔗 Share this article

While the US continues making sweeping revisions to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by expressing skepticism about Covid shots during the global health crisis and has focused upon alleged fatalities following Covid vaccination in her recent position at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Health officials had intended to unveil major changes to the childhood immunization program earlier this month, aligning the US with the Danish national calendar, it is understood – a major change that would put the US at odds with much of the world with insufficient data for improved outcomes. This reveal has been delayed until the new year.

In place of Vinay Prasad, Dr. Høeg is set to address the audience at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth individual to head the office this year.

A Shift at the FDA

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has frequently advocated for discontinuing some childhood immunization guidelines in the US in order to be more similar to Denmark, a nation with nationalized medicine and a citizenry about the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Expertise

The appointee has no obvious experience in drug development, regulation or administrative roles, which has been standard for former leaders of the CBER. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in managing a major agency. She is not an expert in drug approvals.”

Former commissioners of the center would “grasp laws and regulations and the research of drug development”, noted Janet Woodcock. “Clearly, she doesn’t have the type of experience that prior appointees who ran CBER have had.”

CDER has an immense range of responsibilities at the FDA, Woodcock pointed out.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office authorizes numerous generic drugs. There is also a biologic copycat branch, over-the-counter program and more, and each of these have to be supervised,” she explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial management element to the job, which supervises over 5,000 employees. “It’s a huge leadership role, if you perform it correctly,” she said.

Agency Reaction and Disputed Policies

In response to questions about Høeg’s fitness for the role and whether this appointment indicates greater collaboration among agency officials on vaccines, a press secretary stated that the “concerns stem from inaccurate premises”.

“Her experience is consistent with the duties of her position,” the spokesperson explained, pointing to the period Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg assumes responsibility for the agency head's new expedited review system, a disputed one-day medication authorization process that apparently troubled her preceding directors. “How are these therapies being chosen for this voucher program? Who takes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of most medications, aside from shots.”

Established Past Work on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if problematic, past, some experts have noted. She released a study using non-validated crowd-sourced reports to assess the rate of myocarditis after Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are more dangerous than they are.

Part of her “desired changes” for the new federal leadership included altering rules for novel immunizations and ending “unnecessary” vaccines, she stated following the vote on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of barring adolescent males from getting Covid vaccinations.

“She’s an complete dogmatist who starts off with her preconceived notions and tailors the evidence to fit the science in a highly deceptive, dishonest manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|